Zaborny B A, Lukacsko P, Barinov-Colligon I, Ziemniak J A
Department of Clinical Development, Rhône-Poulenc Rorer, Fort Washington, Pennsylvania.
J Clin Pharmacol. 1992 May;32(5):463-9. doi: 10.1002/j.1552-4604.1992.tb03863.x.
The systemic exposure to triamcinolone acetonide (TAA) after inhalation of aerosolized drug has not been examined previously. This study evaluates the plasma concentrations, pharmacokinetics and dose proportionality of TAA after single oral inhalations at doses of 400, 800, and 1600 mcg. Nine moderately asthmatic male patients received each of the doses in a randomized crossover manner using a 1-week washout period between dosing. Serial blood samples were collected for 10 hours postdosing for the determination of plasma TAA concentrations by using a specific radioimmunoassay. The pharmacokinetic profiles that were obtained showed slow and limited absorption over the first 4 hours after dosing followed by rapid elimination with a half-life of approximately 2 hours (range: 1.8-2.3 hr). Comparison of pharmacokinetic parameters from each dose group showed excellent proportionality and consistent absorption for all patients. Mean Cmax values ranged from 0.51 ng/mL after the 400 mcg dose to 1.01 ng/mL and 1.97 ng/mL after the 800 and 1600 mcg doses, respectively. Mean AUC0-10 values for these same doses were 2.6 ng x hr/mL, 5.3 ng x hr/mL and 10.5 ng x hr/mL, respectively. The results suggest that systemic exposure to TAA is minimal after oral inhalation, occurs in a dose proportional fashion, and produces circulating plasma concentrations which are unlikely to have significant adverse systemic effects.
此前尚未对雾化吸入药物后曲安奈德(TAA)的全身暴露情况进行研究。本研究评估了单次口服吸入400、800和1600微克剂量TAA后的血浆浓度、药代动力学及剂量比例关系。9名中度哮喘男性患者以随机交叉方式接受各剂量药物,给药间隔1周洗脱期。给药后10小时内采集系列血样,采用特异性放射免疫分析法测定血浆TAA浓度。所得药代动力学曲线显示,给药后最初4小时吸收缓慢且有限,随后迅速消除,半衰期约为2小时(范围:1.8 - 2.3小时)。各剂量组药代动力学参数比较显示,所有患者的比例关系良好且吸收一致。平均Cmax值在400微克剂量后为0.51纳克/毫升,800微克和1600微克剂量后分别为1.01纳克/毫升和1.97纳克/毫升。相同剂量的平均AUC0 - 10值分别为2.6纳克·小时/毫升、5.3纳克·小时/毫升和10.5纳克·小时/毫升。结果表明,口服吸入TAA后全身暴露极小,呈剂量比例方式发生,产生的循环血浆浓度不太可能产生显著的全身不良反应。